

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

02 Jul 2026

### Targeted $\alpha$ -Therapy in Metastatic Castration Resistant Prostate Cancer with 225Ac-PSMA-617

#### Protocol summary

##### Study aim

The efficiency of endoradiotherapy with 225Ac-PSMA in metastatic castration-resistant prostate cancer patients (mCRPC)

##### Design

This is an interventional clinical trial with a single group design of 10 patients, performing between November 2021 and November 2022 that will be followed between treatment sessions.

##### Settings and conduct

Patients are selected and justified in the nuclear medicine center of the Persian Gulf hospital at Bushehr. The consent form is obtained and finally, the treatment will be performed with intravenous injection of 225-Ac-PSMA-617. After injection, patients will be undergone a whole-body scan for the assessment of radiotracer distribution. Six to eight weeks after the 225-Ac-PSMA-617 therapy, the patients will be visited by oncologists and nuclear medicine physicians and if there was not any toxicity, the next treatment session will be performed.

##### Participants/Inclusion and exclusion criteria

Patients must have had progressive metastatic castration-resistant prostate cancer, positive 68Ga-PSMA-11 PET/CT scan, recovered or stabilized to  $\leq$  Grade 2 from all clinically significant toxicities related to prior prostate cancer therapy, and an ECOG performance status of 0 to 2. Exclusion criteria: Previous treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or Hemi-body irradiation or previous PSMA-targeted radioligand therapy, patients diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment.

##### Intervention groups

We are going to use a single group of patients to evaluate the efficiency of 225-Ac-PSMA-617 in the treatment of prostate cancer.

##### Main outcome variables

The proportion of patients who have a partial, stable (not-progressed), or complete response to therapy.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210612051548N1**

Registration date: **2021-09-22, 1400/06/31**

Registration timing: **prospective**

Last update: **2021-09-22, 1400/06/31**

Update count: **0**

##### Registration date

2021-09-22, 1400/06/31

##### Registrant information

##### Name

Majid Assadi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 77 3332 0361

##### Email address

assadipoya@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-11-22, 1400/09/01

##### Expected recruitment end date

2022-11-22, 1401/09/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Targeted  $\alpha$ -Therapy in Metastatic Castration Resistant Prostate Cancer with 225Ac-PSMA-617

**Public title**

Targeted  $\alpha$ -Therapy in Prostate Cancer

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients must have had progressive metastatic castration-resistant prostate cancer. Patients must have a positive 68Ga-PSMA-11 PET/CT scan. Patients must have recovered or stabilized to  $\leq$  Grade 2 from all clinically significant toxicities related to prior prostate cancer therapy. Patients must have an ECOG performance status of 0 to 2.

**Exclusion criteria:**

Previous treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or hemi-body irradiation or previous PSMA-targeted radioligand therapy. The patient was diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment (Patients with a prior history of malignancy who have been disease-free for more than 3 years are eligible).

**Age**

From **18 years** old

**Gender**

Male

**Phase**

2

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **10**

**Randomization (investigator's opinion)**

N/A

**Randomization description****Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Single

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Research ethics committee of Bushehr university of

medical sciences

**Street address**

Bushehr University of Medical Sciences, Bushehr,Iran

**City**

Bushehr

**Province**

Boushehr

**Postal code**

45654775

**Approval date**

2021-06-27, 1400/04/06

**Ethics committee reference number**

IR.BPUMS.REC.1400.057

**Health conditions studied****1****Description of health condition studied**

Prostate cancer

**ICD-10 code**

C61

**ICD-10 code description**

Malignant neoplasm of prostate

**Primary outcomes****1****Description**

Numbe of treated prostate cancer patients

**Timepoint**

4-6 weeks after last treatment session

**Method of measurement**

Image-based response using 68Ga-PSMA PET/CT

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Intervention group: In this study, the 225Ac-PSMA-617 radiopharmaceutical is injected intravenously into 10 patients with prostate cancers according to the 68Ga-PSMA-11 PET/CT. Then whole-body scan is performed at 24 hours, and 48 hours after injection to assess radiotracer distribution. Six to eight weeks after the 225-Ac-PSMA-617 therapy, the patients will be visited by oncologists and nuclear medicine physicians and if there was not any toxicity, the next treatment session will be performed.

**Category**

Treatment - Drugs

**Recruitment centers**

## 1

### Recruitment center

**Name of recruitment center**

Nuclear Medicine Center, Persian Gulf Hospital

**Full name of responsible person**

Majid Assadi

**Street address**

Persian Gulf Hospital, Taleghani Street, Bushehr, Iran

**City**

Bushehr

**Province**

Boushehr

**Postal code**

45654775

**Phone**

+98 77 3332 0361

**Email**

assadipoya@yahoo.com

### Sponsors / Funding sources

## 1

### Sponsor

**Name of organization / entity**

Boushehr University of Medical Sciences

**Full name of responsible person**

Gholamreza Khamisipour

**Street address**

Vice-Chancellor for Research and Technology of Bushehr University of Medical Sciences, Salman-e-Farsi Blvd, Bushehr, Iran.

**City**

Bushehr

**Province**

Boushehr

**Postal code**

45654775

**Phone**

+98 77 3345 0178

**Fax****Email**

khamisipourgholamreza@gmail.com

**Web page address****Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

**Title of funding source**

Bushehr University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Boushehr University of Medical Sciences

**Full name of responsible person**

Majid Assadi

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Nuclear Medicine

**Street address**

The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Moallem Street, Bushehr, Iran

**City**

Bushehr

**Province**

Boushehr

**Postal code**

45654775

**Phone**

+98 77 3332 0361

**Fax**

+98 77 3332 0361

**Email**

assadipoya@yahoo.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Boushehr University of Medical Sciences

**Full name of responsible person**

Majid Assadi

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Nuclear Medicine

**Street address**

The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Moallem Street, Bushehr, Iran

**City**

Bushehr

**Province**

Boushehr

**Postal code**

45654775

**Phone**

+98 77 3332 0361

**Fax**

+98 77 3332 0361

**Email**

assadipoya@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Boushehr University of Medical Sciences

**Full name of responsible person**

Narges Jokar

**Position**

Research Instructor

**Latest degree**

Master

**Other areas of specialty/work**

Medical Physics

**Street address**

The Persian Gulf Nuclear Medicine Research Center,  
Bushehr University of Medical Sciences, Moallem  
Street, Bushehr, Iran

**City**

Bushehr

**Province**

Boushehr

**Postal code**

45654775

**Phone**

+98 77 3332 0361

**Fax**

+98 77 3332 0361

**Email**

narges.jokar69@gmail.com

**Web page address**

<https://pgnmrc.bpums.ac.ir/fa/index.aspx>

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available

**Title and more details about the data/document**

There is no further information

**When the data will become available and for how long**

There is no further information

**To whom data/document is available**

There is no further information

**Under which criteria data/document could be used**

There is no further information

**From where data/document is obtainable**

There is no further information

**What processes are involved for a request to access data/document**

There is no further information

**Comments**